Bionomics Limited
BNOX
$0.253 4.59%
Exchange: NASDAQ | Sector: Healthcare | Industry: Biotechnology
Q1 2026
Published: Nov 14, 2025

Earnings Highlights

  • EPS of $-4.41 decreased by 41% from previous year
  • Net income of -9.91M
  • "N/A" - N/A
BNOX
Company BNOX

Executive Summary

Bionomics reported a net loss of $9.91 million for QQ1 2026, with an operating loss of $5.65 million and an EBITDA loss of $5.65 million. Research and development expenses amounted to $3.79 million and general and administrative expenses to $1.87 million, while revenue remained unreported for the quarter. The company ended the period with cash and cash equivalents of $13.73 million and a net debt position of βˆ’$13.56 million, reflecting a liquidity buffer that supports continued pipeline execution but requires additional funding or value-creating milestones to extend runway. Cash burn from operations was $3.79 million for the quarter, partially offset by $3.25 million of net cash provided by financing activities, resulting in a net cash decrease of $0.56 million during QQ1 2026.

Despite the absence of quarterly revenue, Bionomics maintains a clinical-stage portfolio focused on CNS disorders (notably BNC210) and oncology (including BNC105 and related programs) with ongoing development activity. The balance sheet remains asset-light on a revenue basis but asset-rich due to goodwill and intangibles, and the company continues to emphasize strategic collaborations (notably with Merck) as a potential monetization pathway for its pipeline. Near-term catalysts are pipeline readouts and any licensing/partnering milestones, which could materially alter the liquidity and valuation dynamics if favorable data or partnership terms emerge.

Overall, QQ1 2026 is consistent with clinical-stage biotech dynamics: substantial R&D investment and operating losses are expected until late-stage proof points materialize. Investors should monitor data readouts, partnership discussions, and any changes to the capital plan that affect liquidity and strategic optionality.

Key Performance Indicators

Operating Income
Increasing
-5.65M
QoQ: -147.20% | YoY: 67.06%
Net Income
Increasing
-9.91M
QoQ: -187.96% | YoY: 36.66%
EPS
Decreasing
-4.41
QoQ: -102.33% | YoY: -41 503.77%

Revenue Trend

Margin Analysis

Historical Earnings Comparison

PeriodRevenue ($M)EPS ($)YoY GrowthReport
Q1 2026 0.00 -4.41 +0.0% View
Q3 2024 15.00 189.00 +0.0% View
Q2 2024 0.10 -1.10 +569.8% View
Q1 2024 0.00 -15.37 +0.0% View
Q2 2023 0.09 -1.47 -79.8% View